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Background: Crotalaria pallida Ailton is a plant belonging to the Fabaceae family, popularly known as “rattle or
rattlesnake” and used in traditional medicine to treat swelling of the joints and as a vermifuge. Previous
pharmacological studies have also reported anti-inflammatory, antimicrobial and antifungal activities. Nevertheless,
scientific information regarding this species is scarce, and there are no reports related to its possible estrogenic and
mutagenic effects. Thus, the purpose of the present study was to investigate the estrogenic potential of C. pallida
leaves by means of the Recombinant Yeast Assay (RYA), seeking an alternative for estrogen replacement therapy
during menopause; and to reflect on the safe use of natural products to assess the mutagenic activity of the crude
extract from C. pallida leaves, the dichloromethane fraction and stigmasterol by means of the Ames test.
Methods: The recombinant yeast assay with the strain BY4741 of Saccharomyces cerevisiae, was performed with the
ethanolic extract, dichloromethane fraction and stigmasterol isolated from the leaves of C. pallida. Mutagenic
activity was evaluated by the Salmonella/microsome assay (Ames test), using the Salmonella typhimurium tester
strains TA100, TA98, TA97 and TA102, with (+S9) and without (−S9) metabolization, by the preincubation method.
Results: All samples showed estrogenic activity, mainly stigmasterol. The ethanolic extract from C. pallida leaves
showed mutagenic activity in the TA98 strain (−S9), whereas dichloromethane fraction and stigmasterol were found
devoid of activity.
Conclusion: Considering the excellent estrogenic activity performed by stigmasterol in the RYA associated with the
absence of mutagenic activity when evaluated by the Ames test, stigmasterol becomes a strong candidate to be
used in hormone replacement therapy during menopause.
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Medicinal plants have been traditionally used worldwide
for the treatment of various human diseases. They have
proved to be abundant sources of biologically active
compounds, many of which have been used as lead
compounds to develop new pharmaceuticals [1].* Correspondence: flaviabiomed@yahoo.com.br
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reproduction in any medium, provided the orCrotalaria pallida Ailton is a species that belongs to the
Fabaceae family, popularly known as “rattle or rattlesnake”
due to the sound of their fruits when dry [2]. This species
is used in traditional medicine, having its roots used to
treat swelling of the joints, and its leaves as vermifuge [3].
Pharmacological studies have demonstrated it also presents
anti-inflammatory, antimicrobial and antifungal functions
[4-8]. However, there are no studies verifying the estrogenic
potential of C. pallida.
One of the current interests, in the pharmacological
area, is to find compounds with estrogenic activity to
replace estrogen in hormone replacement therapy (HRT)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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estrogen, such as the elevation of breast cancer incidence
[9,10]. For this reason, the development of safer and more
effective drugs for menopause treatment is an urgent
priority. Plants appear as a therapeutic option, since some
of their constituents have the ability to bind to estrogen
receptors and to act in preventing the discomfort caused
by the hormonal imbalance associated with menopause.
These constituents are also related to the reduction
of cancer incidence, particularly estrogen-dependent
cancers, such as breast cancer, cardiovascular diseases
and osteoporosis [11-14].
Seeking to find options for drug development, the
estrogenic potential of C. pallida leaves was investigated
using the RYA (Recombinant Yeast Assay), in which
recombinant yeast is utilized as an experimental model
and the transcription of a reporter gene depends on the
presence in the midst of compounds capable of binding
to the estrogen receptor [15].
In the light of finding a good candidate for HRT and
given that natural products are promising sources of novel
potentially therapeutic agents, another purpose of the
present study was to investigate the mutagenic activities
of C. pallida by the Ames test, in order to contribute to




Dimethylsulfoxide (DMSO), nicotinamide adenine di-
nucleotide phosphate sodium salt (NADP), D-glucose-6-
phosphate disodium salt, magnesium chloride, L-histidine
monohydrate, D-biotin, sodium azide (SAZ), 2-anthramine
(2-AA), 4-nitro-o-phenylenediamine (NOPD), mitomycin
C (MMC), 2-aminofluorene (2-AF), 17-β-estradiol,
Triton X-100, SDS 10%, 2-mercaptoethanol and 4-
methylumbelliferyl β-D-galactoside were purchased from
Sigma Chemical Co (St. Louis, USA). Oxoid Nutrient Broth
No. 2 (Oxoid, England) and Difco Bacto Agar (Difco, USA)
were used as bacterial media.
Plant material
Leaves of C. pallida Aiton were collected in Poços de
Caldas, Minas Gerais state, Brazil, and authenticated by
Prof. Dr. Luis Victor Silva Sacramento. The voucher of C.
pallida (BOTU 28656) was deposited at the Herbarium
of the Botanical Institute of São Paulo State University
(UNESP), Botucatu, São Paulo.
Extraction and isolation
The leaves collected were dried in an oven with air circu-
lation at 40°C. The samples were weighed for three days
daily until constant weight. The material was pulverized
and then moistened with 70% ethanol. This material wasthen accommodated in percolator and submitted to
leaching process with 70% ethanol. The extracts were
monitored using TLC-silica gel 60-F254 precoated Al
sheets, using chloroform: methanol: n-propanol:water
(5:6:1:4, v:v) as developing solvent, visualized using UV
(254 and 366 nm) and anisaldehyde sulphuric acid
spray [16], until total depletion of the drug. Following, the
extract was filtered with pleated filter paper and concen-
trated under reduced pressure (40ºC). After lyophilization,
the 70% hydroalcoholic extract was obtained. The chro-
matographic determination of the EtOH 70% extract was
performed by HPLC-DAD (HPLC-PDA, Jasco ®, Column
Phenomenex Synergi Hydro ® RP-18 250 × 4.6 mm id;
4 mm, 1.0 ml min-1, FM: A = H2O with 0.1% formic acid,
B = acetonitrile, linear gradient 0-100% B 60 minutes).
The chromatographic profile obtained from the extract
of the leaves was assessed in a chromatographic com-
parison of the signals observed. Their absorption spectra
(220–400 nm) allowed us to observe the presence of
flavonoids, mainly derivatives of apigenin and luteolin
(flavones) (λ = 254 nm) and phenolic acids and derivatives
(λ = 254 nm) [17].
In order to obtain the dichloromethane fraction by
partition, chromatography was performed (liquid-liquid
extraction - LLE) with dichloromethane (DCM) and
methanol:water (2:8 v/v) (3x), yielding two fractions with
different polarities: a dichloromethane fraction (DCM-Fr)
and an aqueous fraction (Aq-Fr). Each of the fractions
obtained from the LLE rotary evaporator were dried in
order to remove the solvent and then frozen so as to have
their mass determined. The fractions obtained from
the LLE were subjected to a new fractioning using two
techniques: the first dichloromethane fraction (DCM-Fr)
was submitted to chromatography using an open silica gel
column as the stationary phase and hexane mobile phase.
The second technique was applied to the Aq-Fr in Medium
Pressure Liquid Chromatography (MPLC) column using
packed with C18 in the reverse silica and methanol:water
solvent systems. The fractions obtained in the procedure
above were analyzed by HPLC-PDA in order to obtain
a preliminary view of the substances. Comparing the
chromatograms obtained from the MPLC fractions, the
majority of the substances absorbing UV belong to the
class of flavones.
Chromatography by MPLC did not result in the
separation of the pure substance, making a further step
of purification necessary, using a preparative HPLC-
PDA in order to isolate the majority of substances. The
chromatographic analysis of the dichloromethane frac-
tion allowed us to infer that the Fr 23–33 fraction was
practically pure. The isolated substance was called F2.
The 1H NMR spectrum showed characteristic signals
of hydrogen steroid [18]. A comparison of the NMR
chemical shifts of 1 H NMR substance alone, with the
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stigmasterol.
Recombinant yeast assay (RYA)
RYA was performed essentially as in Garcia-Reyero et al.
[15]. Briefly, the yeast strain BY4741 (MATa ura3Δ0 leu2Δ0
his3Δ1 met15Δ0) (EUROSCARF, Frankfurt, Germany),
which was kindly provided by Dr. Benjamin Piña
(CSIC, Barcelona, Spain), was transformed together with
plasmids pH5HE0 and pVitBX2 [15].
The expression plasmid pH5HE0 contained the human
estrogen hormone receptor gene HE0 [19], cloned into
the constitutive yeast expression vector pAAH5 [20]. The
reporter plasmid pVITB2x contained two copies of the
pseudo-palindromic responsive estrogen element from
the Xenopus laevis vitellogenin B1 gene (5’-AGTCACT
GTGACC-3’), inserted into the unique KpnI site of
pSFLΔ-178 K [21].
Transformed clones were first grown in 3 mL of rich
complete medium at 30°C. Following, they were grown
overnight in a minimal medium. The final culture was
adjusted to an optical density (OD) of 0.1 at 600 nm and
distributed in the wells of a siliconized 96-well polypro-
pylene microliter plate (NUNC™, U96 PP 0.5 mL), at
90 μL in the first row. Aliquots of 10 μL of the crude
extract, dichloromethane fraction and stigmasterol at
initial concentrations of 0.01, 0.03 and 0.15 × 10-6 g/mL,
respectively, were dispensed into wells in the first row and
serial dilutions were prepared along the plate, containing
the samples with dilution factors of 1:10, 1:30, 1:90, 1:270
and 1:810. All the used concentrations are determinate in
previous experiments of toxicity.
A positive control was made by adding 17-β-estradiol at
a final concentration of 10 nM. Moreover, we included a
toxicity control by adding 10 nM of 17-β-estradiol to a
sample with a dilution factor of 1:30, and 10% DMSO as
negative control.
Plates were incubated for 6 h at 30°C under 120 rpm.
After incubation, 50 μL of Y-PERTM (PIERCE™, Rockford,
IL, USA) were added to each well and incubated at 30°C
for further 30 min. Afterwards, 50 μL of assay buffer were
added to the lysed cells. The assay buffer was prepared by
mixing 100 mL Z-buffer, 1 mL Triton X-100 (Sigma),
1 mL SDS 10%, 70 μL 2-mercaptoethanol (Fluka) and
21 mg of 4-methylumbelliferyl β-D-galactoside (Sigma).
The Z-Buffer is a combination of: 60 mM Na2HPO4,
40 mM NaH2PO4, 10 mM KCl and 1 mM MgSO4,
pH 7.0.
After centrifugation, plates were read in a spectrofluo-
rometer (Synergy H1, Biotek), at 355 nm excitation and
460 nm emission wavelengths. Fluorescence was recorded
for 20 min (one measurement per min); β-galactosidase
activity was calculated as the rate of increase of fluores-
cence (in arbitrary units). RYA does not provide a directmeasurement of the molar (or mass) concentration of
endocrine disruptors, but of their estrogenic activity.
For simplification, results were calculated as estradiol
equivalents (EEQ), defined as the amount of estradiol that
should be present to account for the observed response in
a given sample. These equivalents were calculated from
the lowest dilution in which the β-galactosidase activity
was indistinguishable from that of the control (only
vehicle).
To translate results from serial dilutions to EEQ, we






In which R0, R, and Rmax represent β-galactosidase
units obtained without ligand (or extract) addition, at a
given ligand concentration [L], and at a saturating ligand
concentration, respectively. Kd represents the dissociation
constant of the ligand–hormone complex; its value
coincides with EC50, the ligand concentration giving 50%
of the maximal response. For extract serial dilutions,
plotting dilution factors versus relative response followed
an inverse sigmoidal function, in which the apparent EC50
correspond to the dilution (actual or theoretical) giving
50% the response for 10 nM estradiol. Apparent EC50 values
for each sample (a minimum of two replicas with at least
four points each) were calculated using standard non-
linear regression methods. These values were converted to
EEQ by assuming they correspond to the EC50 of estradiol
[22], 7.29 × 10-9 g/mL in our assay. Three independent
experiments were done with the compounds, all of them
in triplicate.
Salmonella/microsome assay
Mutagenic activity was evaluated by the Salmonella/micro-
some assay, using the Salmonella typhimurium tester
strains TA98, TA100, TA97a and TA102, which were
kindly provided by Dr. B.N. Ames (Berkeley, CA, USA),
with (+S9) and without (−S9) metabolization, using the
preincubation method [23]. The strains were grown over-
night from frozen cultures for 12–14 h in Oxoid Nutrient
Broth No. 2. The metabolic activation mixture (S9 fraction),
prepared from livers of Sprague–Dawley rats treated
with the polychlorinated biphenyl mixture Aroclor 1254
(500 mg/kg), was purchased from Molecular Toxicology
Inc. (Boone, NC, USA) and freshly prepared before each
test. The metabolic activation system consisted of
4% S9 fraction, 1% 0.4 M MgCl2, 1% 1.65 M KCl, 0.5%
1 M D-glucose-6-phosphate disodium and 4% 0.1 M
NADP, 50% 0.2 M phosphate buffer and 39.5% sterile
distilled water [23]. For the determination of the mutagenic
activity, five different concentrations of each sample
Table 1 Estrogenic activity expressed through the values
of estradiol equivalents (EEQ) ± standard deviation of the
extracts and EC50 values of the ethanol extract of C.
pallida, dichloromethane fraction and stigmasterol using
a genetically modified strain of S. cerevisae BY4741
Samples EEQ (nM) M ± SD EC50 (g/mL)
Ethanolic extract 14.3 ± 4.1 0.2
Dichloromethane fraction 89.0 ± 16.0 0.1
Stigmasterol 122.0 ± 11 10.5 × 10-7
17-β-estradiol - 7.29 × 10-9
EEQ, Values of estradiol equivalents (EEQ); M ± SD, Mean and standard
deviation; EC50, Concentration of sample equivalent to 50% of the activity.
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for dichloromethane fraction and 0.02 to 0.5 mg/plate
for stigmasterol), diluted in DMSO, were assayed. The
mutagenic activity of the dichloromethane fraction and
of the stigmasterol was only evaluated in the TA98
strain, because of the small amount of material available
for the study and based in the fact that initially mutagenic
activity was only observed for TA98. The concentrations
of the samples were selected based on a preliminary
toxicity test. In all subsequent assays, the upper limit
of the dose range tested was either the highest non-toxic
dose or the lowest toxic dose determined in this preliminary
assay. Toxicity was detected either as a reduction in the
number of histidine revertants (His+), or as a thinning of
the auxotrophic background (i.e., background lawn).
The various concentrations of extract, fraction and iso-
lated substance to be tested were added to 0.5 mL of
0.2 M phosphate buffer or to 0.5 mL of 4% S9 mixture,
with 0.1 mL of bacterial culture and then incubated at


























Figure 1 Estrogenic response for extract of C. pallida leaves in the rec
pallida leaves (μg/well) were added to genetically engineered, estrogen- re
activities were calculated as fluorescence units (FU). Values are averages of
control, DMSO, FU = 355 ± 21; positive control, 17-β-estradiol, FU = 9834 ± 9added and the mixture poured on to a plate containing
minimal agar.
The plates were incubated at 37°C for 48 h and the
His+ revertant colonies were counted manually. All
experiments were analyzed in triplicate. The results were
analyzed with the statistical software package Salanal 1.0
(U.S. Environmental Protection Agency, Monitoring
Systems Laboratory, Las Vegas, NV, from the Research
Triangle Institute, RTP, NC, USA), adopting the model of
Bernstein et al. [24]. The data (revertants/plate) were
assessed by means of the analysis of variance (ANOVA),
followed by linear regression. The mutagenicity ratio (MR)
was also calculated for each concentration tested, this
being the mean number of revertants per plate with the
test compound divided by the mean number of revertants
per plate with the negative (solvent) control. A test solution
was considered mutagenic when a dose–response relation-
ship was detected and a two-fold increase in the number of
mutants (MR ≥ 2) was observed in at least one concentra-
tion [1]. The standard mutagens used as positive controls
in experiments without the S9 mix were NOPD (10 μg/
plate) for TA98 and TA97a, SAZ (1.25 μg/plate) for TA100
and MMC (0.5 μg/plate) for TA102. In experiments with
S9 activation, 2-AA (1.25 μg/plate) was used with TA98,
TA97a and TA100 and 2-AF (10 μg/plate) with TA102.
DMSO served as negative (solvent) control.
Results
Estrogenicity assay (RYA)
The result of the estrogenic activity assessment, performed
using the RYA, was given as equivalent to estradiol (EEQ)
and EC50 (Table 1). The extract from C. pallida leaves
obtained an EEQ of 14.3 nM in the RYA, whereas the
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Figure 2 Estrogenic response for extract dichloromethane fraction of C. pallida, in the recombinant yeast assay. Different concentrations
of dichloromethane fraction of C. pallida, (μg/well) were added to genetically engineered, estrogen- responsive yeast cells and incubated for 6 h.
The β-galactosidase activities were calculated as fluorescence units (FU). Values are averages of three independent experiments; bars indicate
value ranges. Negative control, DMSO, FU = 432 ± 34; positive control, 17-β-estradiol, FU = 11490 ± 496.
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Regarding the EC50 values, stigmasterol proved to be the
most potent sample, with EC50 values of 10.5 × 10
-7 g/mL.
Figure 1 shows the estrogenic activity, assessed by the
β-galactosidase activity expressed in arbitrary units of
fluorescence of five concentrations of the extract. It is
possible to observe that the different concentrations tested
presented significant enzymatic activation when compared
to the negative control and the estrogenic activity of the
extract starting from the second lowest concentration.
The dichloromethane fraction (Figure 2) also generated an
increase of fluorescence units, even at lower concentration
that is similar to the second lowest concentration of the
extract. The concentration of 18.9 μg/well provided the
greatest estrogenic activity for this sample. Figure 3 shows
the estrogenic activity, expressed in fluorescence units, for
























Figure 3 Estrogenic response for stigmasterol, isolated from C. pallida
stigmasterol, (μg/well) were added to genetically engineered, estrogen- res
activities were calculated as fluorescence units (FU). Values are averages of
control, DMSO, FU = 54 ± 16; positive control, 17-β-estradiol, FU = 9678 ± 16fluorescence was compared to negative control. This
sample generated a significant activation of the β-
galactosidase enzyme, at all concentrations tested, and
the units of fluorescence were greater than those found in
the negative control.
Mutagenicity assay (Ames test)
Table 2 shows the mean number of revertants/plate, the
standard deviation (SD) and the MR after treatment with
the five concentrations of crude extract, observed in S.
typhimurium strains TA98, TA100, TA97a and TA102,
in the presence (+S9) and absence (−S9) of metabolic
activation. The mutagenic activity was considered negative
for the strains TA97, TA102 and TA100 at all concentra-
tions tested, both in the absence and in the presence of
metabolism. However, in the absence of the external
metabolizing system (−S9), the crude extract was mutagenic,ation (µg/well)




leaves, in the recombinant yeast assay. Different concentrations of
ponsive yeast cells and incubated for 6 h. The β-galactosidase
three independent experiments; bars indicate value ranges. Negative
7.
Table 2 Mutagenic activity expressed by the mean number of revertants/plate ± standard deviation and mutagenicity ratio (in brackets) of the ethanol extract
of C. pallida leaves in S. typhimurium strains in the absence (−S9) and in the presence of metabolism (+S9)
Extract from Crotalaria pallida leaves
Treatment TA97a TA102 Treatment TA100 Treatment TA98
mg/plate -S9 +S9 -S9 +S9 mg/plate -S9 +S9 mg/plate -S9 +S9
DMSO 108 ± 4 140 ± 21 170 ± 6 196 ± 10 DMSO 110 ± 0,6 185 ± 6 DMSO 43 ± 2 20 ± 4
0.7 129 ± 14 (12) 177 ± 12 (1.3) 150 ± 24 (0.9) 224 ± 6 (1.1) 0.9 122 ± 2 (1.1) 237 ± 13 (1.3) 1.8 51 ± 0 (1.2) 18 ± 2 (0.9)
1.9 119 ± 4 (1.1) 164 ± 2 (1.2) 143 ± 5 (0.8) 251 ± 5 (1.3) 2.3 106 ± 7 (1.0) 295 ± 51 (1.1) 4.5 65 ± 8 (1.5) 18 ± 1 (0.9)
3.7 109 ± 5 (1.0) 141 ± 5 (1.0) 146 ± 6 (0.9) 275 ± 19 (1.4) 4.5 145 ± 5 (1.3) 203 ± 3 (1.1) 9.0 95 ± 13* (2.2) 17 ± 2 (0.9)
5.6 97 ± 3 (0.9) 134 ± 12 (1.0) 128 ± 5 (0.8) 265 ± 8 (1.4) 6.8 118 ± 6 (1.1) 222 ± 8 (1.2) 13.5 95 ± 22* (2.2) 21 ± 2 (1.0)
7.4 117 ± 6 (1.1) 174 ± 4 (1.2) 194 ± 5 (1.1) 219 ± 2 (1.1) 9.0 83 ± 5 (0.8) 167 ± 36 (0.9) 18.0 77 ±12 (1.8) 19 ± 1 (0.9)
Control + 1488 ± 18a 2253 ± 56b 1720 ± 26c 1168 ± 28d Control + 1312 ± 60e 1195 ± 157b Control + 1050 ± 39a 1063 ± 24b
*p < 0.05 (ANOVA); Negative Control: dimethyl sulfoxide (DMSO - 100 μL/plate); Positive Control (Control+); a4-nitro-o-phenylenediamine (10.0 μg/plate); b2-anthramine (1.25 μg/plate); cmitomycin (0.5 μg/plate);
























Table 4 Mutagenic activity expressed by the mean
number of revertants/plate ± standard deviation and
mutagenicity ratio (in brackets) of stigmasterol, isolated
substance of dichloromethane fraction of C. pallida
leaves in S. typhimurium strain (TA98) in the absence
(−S9) and in the presence of metabolism (+S9)
Stigmasterol
Treatment TA 98
mg/plate - S9 +S9
DMSO 16 ± 2 25 ± 2
0.02 16 ± 3 (1.0) 31 ± 4 (1.2)
0.04 17 ± 2 (1.1) 23 ± 4 (0.9)
0.09 15 ± 1 (0.9) 27 ± 2 (1.1)
0.18 17 ± 0 (1.1) 22 ± 1 (0.9)
0.5 19 ± 1 (1.2) 30 ± 5 (1.2)
Control + 815 ± 21a 1531 ± 36b
Negative Control: dimethyl sulfoxide (DMSO - 100 μL/plate); Positive
Control (Control+); a4-nitro-o-phenylenediamine (10.0 μg/plate);
b2-anthramine (1.25 μg/plate).
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tions of 9.0 and 13.5 mg/plate in the TA98 strain. Thus, the
Ames test was applied to the fraction and to stigmasterol
in the same conditions, using the TA98 strain, since the
extract showed mutagenic activity for this strain.
As shown in Table 3, no mutagenic activity was observed
for the dichloromethane fraction at any of the concentra-
tions examined for TA98 strain. Stigmasterol was not found
mutagenic for the TA98 strain in the presence and absence
of metabolizing enzymes either. As shown in Table 4, no
MR greater than 2 was observed.
Discussion
RYA was used to identify compounds with structurally
similar estrogenic activity to the natural estrogen, 17-β-
estradiol, and which can interact with the ER. This test
utilizes an engineered yeast strain that harbors two foreign
genetic elements: a vertebrate receptor, in this case, a
human estrogen receptor (ER), and a reporter gene,
whose expression is made dependent on the presence of
estrogens and whose final product concentration is easy
to measure [25].
The samples showed significant estrogenic activity when
evaluated by RYA. The crude extract of C. pallida leaves
showed an equivalent value to estradiol of 14.5 nM, which
evidences that this extract has compounds with affinity
for the ER present in yeast. The extract promoted a
significant activation of the β-galactosidase enzyme, which
could be observed due to the high fluorescence units. The
same could be observed with the dichloromethane frac-
tion, which presented an equivalent value to estradiol of
89.0 nM and promoted a high value of fluorescence units.
Since the dichloromethane fraction of leaves from this
plant stood out due to their estrogenic potential, there wasTable 3 Mutagenic activity expressed by the mean number
of revertants/plate ± standard deviation and mutagenicity
ratio (in brackets) of dichloromethane fraction of C. pallida
in S. typhimurium strain (TA98) in the absence (−S9) and in
the presence of metabolism (+S9)
Dichloromethane fraction of C. pallida
Treatment TA98
mg/plate -S9 +S9
DMSO 14 ± 3 27 ± 3
0.3 19 ± 2 (1.4) 29 ± 6 (1.1)
0.9 15 ± 2 (1.1) 27 ± 2 (1.0)
1.7 15 ± 2 (1.1) 29 ± 5 (1.1)
2.6 17 ± 3 (1.2) 33 ± 4 (1.2)
3.4 19 ± 4 (1.4) 31 ± 2 (1.1)
Control+ 751 ± 96a 1088 ± 109b
Negative Control: dimethyl sulfoxide (DMSO - 100 μL/plate); Positive
Control (Control+); a4-nitro-o-phenylenediamine (10.0 μg/plate);
b2-anthramine (1.25 μg/plate).a great interest in discovering the substance responsible
for the activity that was so evident in the leaves.
The chromatographic profile of the leaves revealed the
presence of flavones, for instance apigenin and luteolin
derivates. Flavonoids have some structural similarities to
the natural estrogen 17-β-estradiol, as well as to other
steroid hormones and steroid hormone antagonists [26],
and can interact with the ER and induce gene expression
similar to that induced by estrogens, albeit at a lower
affinity [27].
Regarding the structure of flavonoids and their possible
estrogenic activity, Zand et al. [26] reported that hydroxyl
at the 6, 7 or 4’ positions of the flavonoid provides greater
estrogenic activity and more potent compounds with 2–4
hydroxyl groups, namely, at least one in the 7 position of
the ring A and another in the 4’ position of ring B. The
presence of these hydroxyl groups is essential for the
estrogenic activity because they mimic the hydroxyl at the
3 and 17 position, found in the 17-β-estradiol molecule
[28]. Furthermore, the presence of a double bond between
carbons 2 and 3 of the ring C is essential for the estrogenic
activity [26]. These structural features are exhibited by
the apigenin and luteolin molecules, which allow a good
interaction with ER.
However, derivatives of flavonoids, such as apigenin and
luteolin, usually appear glycosylated [29], and this glyco-
sylation can eliminate the free hydroxyl that is essential
for the interaction with ERs or substituents may provide
steric hindrance that also hinders the interaction with ERs.
Furthermore, the ortho positioning between two hydroxyl
groups may serve to reduce estrogenicity, due to the avoid-
ance of direct interaction with ER [30], as observed with
the luteolin molecule. Thus, these flavones were probably
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extract.
In view of the promising results obtained in experiments
with extract of leaves and considering that the extract is a
complex mixture of several unknown organic compounds
[1], the evaluation of isolated compounds is even more
relevant. In this context, stigmasterol was isolated from
the dichloromethane fraction of leaves and, following, its
estrogenic activity assessed by RYA.
The results for stigmasterol in RYA showed that it is
highly likely that this substance is responsible for the
high estrogenicity found in leaves of C. pallida, since
it was able to provide the highest result equivalent to
estradiol (122.0 nM) and an important EC50 value of
10.5 × 10-7 g/mL.
Stigmasterol belongs to the class phytosteroids extracted
from species of plants. Among the most common
phytosteroids are β-sisterol, campesterol and stigmasterol.
Chemically, they are alcohols consisting of 28 or 29
carbon atoms, similar to cholesterol [31].
The advantages of phytosteroids result from its bio-
degradability, the ability to affect numerous biological
processes through membranes, to bind to specific hormone
receptors and to be modified by synthetic methods [32-34].
The structural similarity between the molecule and
stigmasterol from 17-β-estradiol (Figure 4) is remarkable,
justifying the high estrogenic activity found in this sample
by means of the RYA.
Since one of the purposes of this study was to search
for compounds with estrogenic activity that could be used
in hormone replacement therapy, the results obtained for
the samples, mainly for stigmasterol, in the RYA, make
these substances possible candidates.
Regarding the safe use of natural products, the muta-
genic activity of the crude extract of C. pallida leaves,
dichloromethane fraction and stigmasterol were assessed
by the Ames test. Although the crude extract of C. pallida
leaves showed good results when assessed as for its estro-
genic activity, it proved to be mutagenic when evaluated
by the Ames test. The extract was mutagenic for the TA98
strain, in the absence of metabolic activity. This allows usStigmasterol                  
Figure 4 Structural similarity between stigmasterol and 17-β-estradioto state that this extract has direct mutagens acting as per
the mechanism of frameshift.
In relation to the study of the mutagenic potential of
flavonoids, Rietjens et al. [35] have described essential
features in the flavonoid structure for the mutagenic
activity to be present, such as: a free hydroxyl at the 3
position of the ring C, double bond between the 2 and 3
positions and the keto group at the 4 position. These
characteristics are fundamental for the presence of
mutagenic activity because they allow the hydroxyl at the
3 position to tautomerize molecule for molecule 3-keto.
However, the apigenin and luteolin molecules do not have
hydroxyl at the 3 position of the ring C, which may
suggest that these substances are not responsible for
the mutagenic activity found in the extract.
The literature reports that pyrrolizidine alkaloids are
often found in Crotalaria species, including C. pallida
[36,37]. Previous studies have demonstrated that alkaloids
are able to induce chromosomal aberrations in the CHO
(Chinese Hamster Ovary) [38] cell line, mutagenicity in
Chinese hamster lung cells (CHL) [39], sister chromatid
exchange in human peripheral lymphocytes [40] and in-
crease the frequency of micronuclei and sister chromatid
exchange in meristematic cells of Allium cepa [41].
The hepatotoxic activity of pyrrolizidine alkaloids
probably results from the high reactivity of alkylating
pyrrole derivatives, generated during enzymatic metabolism
[42]. Both alkaloid molecules and metabolites are reactive
alkylating agents capable of forming covalent bonds
with stable macromolecules [43,44]. Due to the ability
of pyrrolizidine alkaloids to interact with the genetic
material, their involvement has been evidenced with
mutagenicity and carcinogenesis [43].
In this study, the dichloromethane fraction and stigmas-
terol did not show mutagenic activity when evaluated
by the Ames test in the TA98 strain. Considering the
promising estrogenic activity of this isolated substance, a
lack of mutagenic effect in bacterial systems is highly
relevant.
Phytosterols such as stigmasterol are known as antioxi-
dants [45], playing a role in the chemoprevention of DNA                     17-β-estradiol
l.
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http://www.biomedcentral.com/1472-6882/13/216damage induced by oxidative radicals [46]. The exact
mechanism by which phytosteroids offer protection
against cancer is not understood, but there are theories
proposing their effect on the structure of cell membranes,
on the fluidity of cell membranes, on enzymes bound to
membranes, on signal transduction pathways, on apoptosis,
on membrane integrity, on the immune function, on the
estrogenic properties on the tissue and on acids and neutral
steroids in the colon [31].
Lim et al. [47] reported stigmasterol as a substance
with high antimutagenic activity in Gleditsia sinensis
Lam, Leguminosae, obtaining a reduction of 51.2% and
64.2% of mutagenicity against MNNG (N-methyl-N’-nitro-
nitrosoguanidine) and 4-NQO (4-nitroquinoline-N-oxide)
mutagens, respectively, by means of in vitro assay, referring
to the application of stigmasterol as an anticancer agent,
but emphasizing the need for in vivo studies. Substances
with antimutagenic potential increase the efficiency of the
repair mechanisms of mutations caused by mutagens or
cause the inactivation of the mutagenic substance. As a
result, these substances act as protective agents, reducing
the frequency of DNA damage. In both cases, however,
they act before the disordered multiplication of cells or
tumor formation [48].
Considering the promising estrogenic activity and that
stigmasterol might be successfully incorporated into
pharmaceutical products, the absence of a mutagenic
effect in the Ames assay is a positive step towards deter-
mining its safe use in hormone replacement therapy
during menopause.Conclusions
In conclusion, this study evidenced that the crude extract
of C. pallida leaves has an estrogenic effect. Nevertheless,
the present results indicate that this extract should be used
with caution because it might be mutagenic. Considering
that medicinal herbs contain complex mixtures of thou-
sands of components that can act alone or synergistically,
the estrogenic activity of dichloromethane fraction and
stigmasterol isolated from C. pallida leaves with absence
of a mutagenic effect in the Ames assay is highly relevant,
since these samples may be successfully incorporated
into pharmaceutical products with an important role in
hormone replacement therapy.Abbreviations
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